Bone Metabolism and Histomorphometric Changes in Murine Models Treated with Sclerostin Antibody: A Systematic Review

Author(s): Srijit Das, Rajalingham Sakthiswary.

Journal Name: Current Drug Targets

Volume 14 , Issue 14 , 2013

Become EABM
Become Reviewer


Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub- Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness

Keywords: Bone formation, bone histomorphometry, bone metabolism, sclerostin antibody.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1667 - 1674]
Pages: 8
DOI: 10.2174/1389450114666131217001756
Price: $65

Article Metrics

PDF: 29